
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Monday.
Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) rose sharply during Monday's session after the company announced top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra, as first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma, including cancers of the stomach, gastroesophageal junction and esophagus.